Diamond Biotechnology Balance Sheet Health
Financial Health criteria checks 4/6
Diamond Biotechnology has a total shareholder equity of NT$612.6M and total debt of NT$301.9M, which brings its debt-to-equity ratio to 49.3%. Its total assets and total liabilities are NT$1.0B and NT$428.9M respectively. Diamond Biotechnology's EBIT is NT$98.7M making its interest coverage ratio 13.6. It has cash and short-term investments of NT$224.1M.
Key information
49.3%
Debt to equity ratio
NT$301.86m
Debt
| Interest coverage ratio | 13.6x |
| Cash | NT$224.14m |
| Equity | NT$612.55m |
| Total liabilities | NT$428.90m |
| Total assets | NT$1.04b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6815's short term assets (NT$673.3M) exceed its short term liabilities (NT$231.8M).
Long Term Liabilities: 6815's short term assets (NT$673.3M) exceed its long term liabilities (NT$197.1M).
Debt to Equity History and Analysis
Debt Level: 6815's net debt to equity ratio (12.7%) is considered satisfactory.
Reducing Debt: 6815's debt to equity ratio has increased from 37.8% to 49.3% over the past 5 years.
Debt Coverage: 6815's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 6815's interest payments on its debt are well covered by EBIT (13.6x coverage).